Exicure, Inc.

NasdaqCM:XCUR

Sector

🏥 Health Care

Industries

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 41.07 M

Share Price

USD 6.50

Avg Daily Volume

20,585

Change (1 day)

-12.98%

Change (1 year)

282.35%

Change (YTD)

-52.45%

Exicure, Inc. Enterprise Value to EBITDA (EV/EBITDA) on June 23, 2025

Exicure, Inc. Enterprise Value to EBITDA (EV/EBITDA) is NA on June 23, 2025. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.

Exicure, Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 23, 2025, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Exicure, Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 23, 2025, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Exicure, Inc. average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.

Daily

From:

To:

Zoom:

Key data

Date	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield	Market Capitalization

NasdaqCM: XCUR

Exicure, Inc.

CEO	Mr. Andy Yoo
IPO Date	May 22, 2018
Location	United States
Headquarters	2430 North Halsted Street
Employees	7
Sector	🏥 Health Care
Industries Biotechnology 💊 Pharmaceuticals

Description

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.